Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Sudhir Ghandikota"'
Autor:
Pooja Khandelwal, Dana T Lounder, Allison Bartlett, Yael Haberman, Anil G. Jegga, Sudhir Ghandikota, Jane Koo, Nathan Luebbering, Daniel Leino, Sheyar Abdullah, Michaela Loveless, Phillip Minar, Kelly Lake, Bridget Litts, Rebekah Karns, Adam S. Nelson, Lee A. Denson, Stella M. Davies
Publikováno v:
Haematologica, Vol 108, Iss 7 (2023)
We performed transcriptomic analyses on freshly frozen (n=21) and paraffin-embedded (n=35) gastrointestinal (GI) biopsies from children with and without acute acute GI graft-versus-host disease (GvHD) to study differential gene expressions. We identi
Externí odkaz:
https://doaj.org/article/4fe814e572894a2582f0fd589687275a
Autor:
Rajesh K Kasam, Sudhir Ghandikota, Divyalakshmi Soundararajan, Geereddy B Reddy, Steven K Huang, Anil G Jegga, Satish K Madala
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 9, Pp 1-16 (2020)
Abstract Fibroblast activation including proliferation, survival, and ECM production is central to initiation and maintenance of fibrotic lesions in idiopathic pulmonary fibrosis (IPF). However, druggable molecules that target fibroblast activation r
Externí odkaz:
https://doaj.org/article/2a97e233e5134721ba0d532a1b18172e
Publikováno v:
BMC Bioinformatics, Vol 21, Iss 1, Pp 1-14 (2020)
Abstract Background Admixed populations arise when two or more previously isolated populations interbreed. A powerful approach to addressing the genetic complexity in admixed populations is to infer ancestry. Ancestry inference including the proporti
Externí odkaz:
https://doaj.org/article/62599b92018340b9ba4324e2df803057
Publikováno v:
STAR Protocols, Vol 2, Iss 4, Pp 100873- (2021)
Summary: Standard transcriptomic analyses cannot fully capture the molecular mechanisms underlying disease pathophysiology and outcomes. We present a computational heterogeneous data integration and mining protocol that combines transcriptional signa
Externí odkaz:
https://doaj.org/article/90b2d06ad9e3475bb471937ead5c80dc
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 10, p 5447 (2022)
Idiopathic pulmonary fibrosis (IPF) is a severe fibrotic lung disease characterized by irreversible scarring of the lung parenchyma leading to dyspnea, progressive decline in lung function, and respiratory failure. We analyzed lung transcriptomic dat
Externí odkaz:
https://doaj.org/article/4f94939fbe8a418db394ddedb499daa1
Autor:
Yunguan Wang, Jaswanth K. Yella, Sudhir Ghandikota, Tejaswini C. Cherukuri, Harshavardhana H. Ediga, Satish K. Madala, Anil G. Jegga
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Background: There are two US Food and Drug Administration (FDA)-approved drugs, pirfenidone and nintedanib, for treatment of patients with idiopathic pulmonary fibrosis (IPF). However, neither of these drugs provide a cure. In addition, both are asso
Externí odkaz:
https://doaj.org/article/9955bde817bc4380bf3f9f7ed99d832c
Publikováno v:
2022 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82da69ceba05862669d967f6cf6d8b69
https://doi.org/10.1109/bibm55620.2022.9995233
https://doi.org/10.1109/bibm55620.2022.9995233
Autor:
Amit Kumar, Sierra R. Bruno, Mona Ruban, Ying-Wai Lam, Joseph Walzer, Yvonne M. W. Janssen-Heininger, Sudhir Ghandikota, Z. Mark, Vikas Anathy, Nicolas Chamberlain, Ravishankar Chandrasekaran, Anil G. Jegga, Bethany Korwin Mihavics, Clarissa S. Gold, Evan Elko, Jose L. Gomez
Publikováno v:
Thorax. 77:669-678
BackgroundThe role of club cells in the pathology of idiopathic pulmonary fibrosis (IPF) is not well understood. Protein disulfide isomerase A3 (PDIA3), an endoplasmic reticulum-based redox chaperone required for the functions of various fibrosis-rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::304ecb8dce8d84ee5e30860050ab8fcb
https://doi.org/10.1136/thoraxjnl-2021-216882
https://doi.org/10.1136/thoraxjnl-2021-216882
Publikováno v:
Allergy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b91489c97239b9d3d0e965abc4a708d
https://doi.org/10.1111/all.14219
https://doi.org/10.1111/all.14219
Autor:
Tejaswini C Cherukuri, Harshavardhana H Ediga, Sudhir Ghandikota, Jaswanth Yella, Anil G. Jegga, Yunguan Wang, Satish K. Madala
Publikováno v:
Therapeutic Advances in Respiratory Disease
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Background:There are two US Food and Drug Administration (FDA)-approved drugs, pirfenidone and nintedanib, for treatment of patients with idiopathic pulmonary fibrosis (IPF). However, neither of these drugs provide a cure. In addition, both are assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab5e723972dce7c24df26bfc91b09bf
http://europepmc.org/articles/PMC7659024
http://europepmc.org/articles/PMC7659024